I chose this specialty because I have always had an interest in diseases of the blood. My patients can be confident knowing I provide optimal individual patient care based on precision diagnosis and targeted therapy. Although I treat many types of blood diseases, my area of expertise is chronic lymphocytic leukemia.

Conditions I Treat:

- Chronic lymphocytic leukemia/Small lymphocytic lymphoma (CLL)
- Hairy cell leukemia
- Prolymphocytic leukemia
- Lymphoplasmacytic lymphoma (Waldenstrom's macroglobulinemia)
- Large granular lymphocytic leukemia

Certified Specialties

Hematology - American Board of Internal Medicine

Faculty Appointments

Professor - Department of Medicine, Hematology/Oncology (SMD)

Credentials

Residency & Fellowship

Residency, Internal Medicine, University of Arkansas College of Medicine. 1996 - 1997

Fellowship, Hematology & Oncology, University of Chicago Medical Center. 1993 - 1996

Residency, Internal Medicine, Groote Schuur Hospital (South Africa). 1987 - 1991

Internship, Internal Medicine, Coronation Hospital (South Africa). 1984 - 1984

Education

MBBCH | University of Witwatersrand (South Africa). 1983

Awards

Hematology Teacher of the Year. 2023 - 2024

Teacher of the Year in Hematology. 2008

Kaminer Fellowship (Travel Award). 1995

Degree with Distinction. 1983

Research

Dr. Zent's research has improved our understanding of the therapeutic monoclonal antibodies used to treat CLL, use of molecular prognostic markers in the management of CLL, diagnosis of CLL and related diseases, and evaluation and management of autoimmune cytopenias and second malignancies complica...

Research Lab

Visit Research Lab Website

Clinical Trials

A Phase II Randomized Study Comparing Ibrutinib and Rituximab Vs Venetoclax and Rituximab in Previously Untreated Waldenstrom's Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma (LPL)

Lead Researcher: Clive S Zent

This phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab in treating patients with previously untreated Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Ibrutinib may stop the growth of c...

Publications

Journal Articles

Hairy cell leukemia variant and WHO classification correspondence Re: 5 edition WHO classification haematolymphoid tumors: lymphoid neoplasms.

Grever M, Andritsos L, Anghelina M, Arons E, Banerji V, Barrientos J, Bhat SA, Blachly J, Broccoli A, Call T, Dearden C, Dietrich S, Else M, Epperla N, Fagarasanu A, Falini B, Forconi F, Gozzetti A, Hampel P, Hermel DJ, Iyengar S, Johnston JB, Juliusson G, Kreitman RJ, Lauria F, Lozanski G, Oakes CC, Parikh SA, Park J, Quest G, Rai K, Ravandi F, Robak T, Rogers KA, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam CS, Tiacci E, Troussard X, Wörmann B, Zent CS, Zenz T, Zinzani PL

Leukemia.. 2024 July 38 (7):1642-1644. Epub 06/08/2024.

Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia.

Hill BT, Ma S, Zent CS, Baran AM, Wallace DS, Advani AS, Winter AM, Winter JN, Gordon LI, Karmali R, Liesveld JL, Mulford DA, Rowland C, Bui A, Sportelli P, Miskin HP, Weiss MS, Friedberg JW, Barr PM

Blood advances.. 2024 January 238 (2):378-387. Epub 1900 01 01.

Long-term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial Bruton tyrosine kinase inhibitors therapy for chronic lymphocytic leukemia or lymphoplasmacytic lymphoma.

Brady MT, Laniewski N, Strawderman M, Chu CC, Kanagaiah P, Sangster MY, Topham DJ, Friedberg JW, Zent CS

American journal of hematology.. 2023 October 98 (10):E288-E290. Epub 07/23/2023.

Antibody-mediated phagocytosis in cancer immunotherapy.

Van Wagoner CM, Rivera-Escalera F, Jaimes-Delgadillo NC, Chu CC, Zent CS, Elliott MR

Immunological reviews.. 2023 October 319 (1):128-141. Epub 08/21/2023.

Risk of New-Onset Atrial Fibrillation Associated With Targeted Treatment of Lymphoma.

Ojo A, Goldenberg I, McNitt S, Schleede S, Casulo C, Zent CS, Moore J, Soniwala M, Aktas MK, Sherazi S

JACC. Advances.. 2023 October 2 (8):100602. Epub 09/12/2023.

Healthcare Utilization Disparities of Adolescent and Young Adults Compared to the Older Lymphoma Population.

Thapa K, Strawderman M, Reagan PM, Barr PM, Zent CS, Friedberg JW, Faugh T, Casulo C

Clinical lymphoma, myeloma & leukemia.. 2023 September 23 (9):e260-e267. Epub 05/23/2023.

Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia.

Wallace DS, Zent CS, Baran AM, Reagan PM, Casulo C, Rice G, Friedberg JW, Barr PM

Blood advances.. 2023 June 137 (11):2496-2503. Epub 1900 01 01.

Rituximab induced cytokine release with high serum IP-10 (CXCL10) concentrations is associated with infusion reactions.

Moore JE, Bloom PC, Chu CC, Bruno JE, Herne CA, Baran AM, Quataert SA, Mosmann TR, Taylor RP, Wallace DS, Elliott MR, Barr PM, Zent CS

Leukemia research.. 2023 June 129 :107072. Epub 03/29/2023.

Impact of sex on outcomes in patients with hairy cell leukemia. An HCL patient data registry analysis.

Epperla N, Zhao Q, Anghelina M, Neal J, Blachly JS, Rogers KA, Lozanski G, Oakes CC, Bhat SA, Zent CS, Banerji V, Grever M, Andritsos L

American journal of hematology.. 2023 May 98 (5):E116-E118. Epub 02/24/2023.

The role of splenectomy in management of splenic B-cell lymphomas.

Archibald WJ, Baran AM, Williams AM, Salloum RM, Richard Burack W, Evans AG, Syposs CR, Zent CS

Leukemia research.. 2023 May 128 :107053. Epub 03/02/2023.

Arrhythmogenic Cardiotoxicity Associated With Contemporary Treatments of Lymphoproliferative Disorders.

Sherazi S, Schleede S, McNitt S, Casulo C, Moore JE, Storozynsky E, Patel A, Vidula N, Aktas MK, Zent CS, Goldenberg I

Journal of the American Heart Association.. 2023 March 2112 (6):e025786. Epub 03/09/2023.

Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia.

Ravandi F, Kreitman RJ, Tiacci E, Andritsos L, Banerji V, Barrientos JC, Bhat SA, Blachly JS, Broccoli A, Call T, Chihara D, Dearden C, Demeter J, Dietrich S, Else M, Epperla N, Falini B, Forconi F, Gladstone DE, Gozzetti A, Iyengar S, Johnston JB, Jorgensen J, Juliusson G, Lauria F, Lozanski G, Parikh SA, Park JH, Polliack A, Quest G, Robak T, Rogers KA, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam CS, Thompson PA, Troussard X, Zent CS, Zenz T, Zinzani PL, Wörmann B, Rai K, Grever M

Blood cancer journal.. 2022 December 1312 (12):165. Epub 12/13/2022.

Development of a distributed international patient data registry for hairy cell leukemia.

Andritsos LA, Anghelina M, Neal J, Blachly JS, Mathur P, Lele O, Dearden C, Iyengar S, Cross M, Zent CS, Rogers KA, Epperla N, Lozanski G, Oakes CC, Kraut E, Ruppert AS, Zhao Q, Bhat SA, Forconi F, Banerji V, Handunnetti S, Tam CS, Seymour JF, Else M, Kreitman RJ, Saven A, Call T, Parikh SA, Ravandi F, Johnston JB, Tiacci E, Troussard X, Tallman MS, Dietrich S, Tadmor T, Gozzetti A, Zinzani PL, Robak T, Quest G, Demeter J, Rai K, Fernandez SA, Grever M

Leukemia & lymphoma.. 2022 December 63 (13):3021-3031. Epub 09/07/2022.

Corrigendum to "Patient-driven research: Initial results from a prospective health-related quality of life study performed at the request of patients living with hairy cell leukemia" [Leuk. Res. 120 (2022) 106919].

Anghelina M, Naughton MJ, Zhao Q, Ruppert AS, Neal J, Rogers KA, Blachly JS, Lozanski G, Bhat SA, Kraut E, Epperla N, Mathur P, Zent CS, Banerji V, Dearden C, Hutchinson T, Grever M, Andritsos LA

Leukemia research.. 2022 October 121 :106943. Epub 09/02/2022.

Patient-driven research: Initial results from a prospective health-related quality of life study performed at the request of patients living with hairy cell leukemia.

Anghelina M, Naughton MJ, Zhao Q, Ruppert AS, Neal J, Rogers KA, Blachly JS, Lozanski G, Bhat SA, Kraut E, Epperla N, Mathur P, Zent CS, Banerji V, Dearden C, Hutchinson T, Grever M, Andritsos LA

Leukemia research.. 2022 September 120 :106919. Epub 07/18/2022.

The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact.

Pinney JJ, Blick-Nitko SK, Baran AM, Peterson DR, Whitehead HE, Izumi R, Munugalavadla V, Van DerMeid KR, Barr PM, Zent CS, Elliott MR, Chu CC

Haematologica.. 2022 June 1107 (6):1460-1465. Epub 06/01/2022.

Persistent polyclonal B-cell lymphocytosis: Illustration of the great mimicker of low-grade B-cell lymphoma.

Nkosi D, Zent CS, El Hussein S

EJHaem.. 2022 May 3 (2):553-554. Epub 04/19/2022.

Ibrutinib Restores Tumor-specific Adaptive Immunity in Chronic Lymphocytic Leukemia.

Zent CS

Clinical cancer research : an official journal of the American Association for Cancer Research.. 2021 August 1527 (16):4465-4467. Epub 06/09/2021.

Hairy cell leukemia and COVID-19 adaptation of treatment guidelines.

Grever M, Andritsos L, Banerji V, Barrientos JC, Bhat S, Blachly JS, Call T, Cross M, Dearden C, Demeter J, Dietrich S, Falini B, Forconi F, Gladstone DE, Gozzetti A, Iyengar S, Johnston JB, Juliusson G, Kraut E, Kreitman RJ, Lauria F, Lozanski G, Parikh SA, Park J, Polliack A, Ravandi F, Robak T, Rogers KA, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam CS, Tiacci E, Troussard X, Zent C, Zenz T, Zinzani PL, Wörmann B

Leukemia.. 2021 July 35 (7):1864-1872. Epub 05/04/2021.

Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma.

Zent CS, Brady MT, Delage C, Strawderman M, Laniewski N, Contant PN, Kanagaiah P, Sangster MY, Barr PM, Chu CC, Topham DJ, Friedberg JW

Leukemia.. 2021 June 35 (6):1788-1791. Epub 10/30/2020.

Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphoma.

Rodgers TD, Williams AM, Baran A, Reagan PM, Casulo C, Zent CS, Evans A, Friedberg JW, Barr PM

Leukemia & lymphoma.. 2021 March 62 (3):598-605. Epub 10/25/2020.

Targeted therapy for treatment of patients with classical hairy cell leukemia.

Moore JE, Delibert K, Baran AM, Evans AG, Liesveld JL, Zent CS

Leukemia research.. 2021 March 102 :106522. Epub 02/04/2021.

Changing of the guard: Leukemia Research 2021.

Zent CS, Ross DM

Leukemia research.. 2021 January 100 :106510. Epub 01/13/2021.

A Case of Acute Eosinophilic Leukemia with a Novel 6 Mutation.

Lipof JJ, Huselton EJ, Zent CS, Evans A, Zhang B, Rothberg PG, Bennett JM

Case reports in hematology.. 2021 2021 :5574766. Epub 07/03/2021.

Complement Activation in the Treatment of B-Cell Malignancies.

Zent CS, Pinney JJ, Chu CC, Elliott MR

Antibodies.. 2020 December 19 (4)Epub 12/01/2020.

Macrophage hypophagia as a mechanism of innate immune exhaustion in mAb-induced cell clearance.

Pinney JJ, Rivera-Escalera F, Chu CC, Whitehead HE, VanDerMeid K, Nelson AM, Barbeau MC, Zent CS, Elliott MR

Blood.. 2020 October 29136 (18):2065-2079. Epub 1900 01 01.

Cognitive function in patients with chronic lymphocytic leukemia: a cross-sectional study examining effects of disease and treatment.

Williams AM, van Wijngaarden E, Seplaki CL, Heckler CE, Weber MT, Barr PM, Zent CS, Janelsins MC

Leukemia & lymphoma.. 2020 July 61 (7):1627-1635. Epub 03/09/2020.

Additional B-cell malignancies in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL).

Meacham PJ, Williams AM, Strawderman M, Baran AM, Archibald WJ, Wallace DS, Tschernia NP, Burack WR, Barr PM, Zent CS

Leukemia & lymphoma.. 2020 July 61 (7):1636-1644. Epub 03/16/2020.

Multiple B cell malignancies in patients with chronic lymphocytic leukemia: epidemiology, pathology, and clinical implications.

Parikh SA, Meacham PJ, Zent CS, Evans AG

Leukemia & lymphoma.. 2020 May 61 (5):1037-1051. Epub 01/11/2020.

Initial treatment of B-cell prolymphocytic leukemia with ibrutinib.

Moore J, Baran AM, Meacham PJ, Evans AG, Barr PM, Zent CS

American journal of hematology.. 2020 May 95 (5):E108-E110. Epub 01/31/2020.

High-resolution quantification of discrete phagocytic events by live cell time-lapse high-content microscopy imaging.

Chu CC, Pinney JJ, Whitehead HE, Rivera-Escalera F, VanDerMeid KR, Zent CS, Elliott MR

Journal of cell science.. 2020 March 5133 (5)Epub 03/05/2020.

Efficacy of lenalidomide in high-risk diffuse large B-cell lymphoma.

Rodgers TD, Baran A, Reagan PM, Casulo C, Zent C, Evans A, Burack R, Williams AM, Friedberg JW, Barr PM

British journal of haematology.. 2020 February 188 (4):e33-e36. Epub 12/17/2019.

High-resolution quantitation of discrete phagocytic events by live cell time-lapse high-content microscopy imaging.

Chu CC, Pinney JJ, Whitehead HE, Rivera-Escalera F, VanDerMeid KR, Zent CS, Elliott MR

Journal of cell science.. 2020 January 1 Epub 01/01/2020.

Significant weight gain in CLL patients treated with Ibrutinib: A potentially deleterious consequence of therapy.

Williams AM, Baran AM, Schaffer M, Bushart J, Rich L, Moore J, Barr PM, Zent CS

American journal of hematology.. 2020 January 95 (1):E16-E18. Epub 11/03/2019.

CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering.

Oostindie SC, van der Horst HJ, Lindorfer MA, Cook EM, Tupitza JC, Zent CS, Burack R, VanDerMeid KR, Strumane K, Chamuleau MED, Mutis T, de Jong RN, Schuurman J, Breij ECW, Beurskens FJ, Parren PWHI, Taylor RP

Haematologica.. 2019 September 104 (9):1841-1852. Epub 02/21/2019.

Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience.

Williams AM, Baran AM, Casulo C, Reagan P, Friedberg JW, Helber M, Moore J, Baloga E, Zent CS, Barr PM

Clinical lymphoma, myeloma & leukemia.. 2019 January 19 (1):41-47. Epub 10/13/2018.

downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels.

Musilova K, Devan J, Cerna K, Seda V, Pavlasova G, Sharma S, Oppelt J, Pytlik R, Prochazka V, Prouzova Z, Trbusek M, Zlamalikova L, Liskova K, Kruzova L, Jarosova M, Mareckova A, Kornauth C, Simonitsch-Klupp I, Schiefer AI, Merkel O, Mocikova H, Burda P, Machova Polakova K, Kren L, Mayer J, Zent CS, Trneny M, Evans AG, Janikova A, Mraz M

Blood.. 2018 November 29132 (22):2389-2400. Epub 09/13/2018.

Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.

Mato AR, Roeker LE, Allan JN, Pagel JM, Brander DM, Hill BT, Cheson BD, Furman RR, Lamanna N, Tam CS, Handunnetti S, Jacobs R, Lansigan F, Bhavsar E, Barr PM, Shadman M, Skarbnik AP, Goy A, Beach DF, Svoboda J, Pu JJ, Sehgal AR, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Rhodes J, Ujjani CS, Nabhan C

American journal of hematology.. 2018 November 93 (11):1394-1401. Epub 09/26/2018.

Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies.

VanDerMeid KR, Elliott MR, Baran AM, Barr PM, Chu CC, Zent CS

Cancer immunology research.. 2018 October 6 (10):1150-1160. Epub 08/08/2018.

Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.

Mato AR, Thompson M, Allan JN, Brander DM, Pagel JM, Ujjani CS, Hill BT, Lamanna N, Lansigan F, Jacobs R, Shadman M, Skarbnik AP, Pu JJ, Barr PM, Sehgal AR, Cheson BD, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Goy A, Winter AM, Garcia C, Kennard K, Isaac K, Dorsey C, Gashonia LM, Singavi AK, Roeker LE, Zelenetz A, Williams A, Howlett C, Weissbrot H, Ali N, Khajavian S, Sitlinger A, Tranchito E, Rhodes J, Felsenfeld J, Bailey N, Patel B, Burns TF, Yacur M, Malhotra M, Svoboda J, Furman RR, Nabhan C

Haematologica.. 2018 September 103 (9):1511-1517. Epub 06/07/2018.

Management of melanoma in patients with chronic lymphocytic leukemia.

Archibald WJ, Meacham PJ, Williams AM, Baran AM, Victor AI, Barr PM, Sahasrahbudhe DM, Zent CS

Leukemia research.. 2018 August 71 :43-46. Epub 07/06/2018.

Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.

Mato AR, Nabhan C, Thompson MC, Lamanna N, Brander DM, Hill B, Howlett C, Skarbnik A, Cheson BD, Zent C, Pu J, Kiselev P, Goy A, Claxton D, Isaack K, Kennard KH, Timlin C, Landsburg D, Winter A, Nasta SD, Bachow SH, Schuster SJ, Dorsey C, Svoboda J, Barr P, Ujjani CS

Haematologica.. 2018 May 103 (5):874-879. Epub 02/01/2018.

Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies.

Williams AM, Baran AM, Meacham PJ, Feldman MM, Valencia HE, Newsom-Stewart C, Gupta N, Janelsins MC, Barr PM, Zent CS

Leukemia & lymphoma.. 2018 March 59 (3):625-632. Epub 07/11/2017.

Ibrutinib therapy for lymphoplasmacytic lymphoma.

Helber MJ, Moore JE, Williams AM, Meacham PJ, Rothberg PG, Zent CS

American journal of hematology.. 2017 September 92 (9):E542-E544. Epub 06/09/2017.

Hexamerization-enhanced CD20 antibody mediates complement-dependent cytotoxicity in serum genetically deficient in C9.

Taylor RP, Lindorfer MA, Cook EM, Beurskens FJ, Schuurman J, Parren PWHI, Zent CS, VanDerMeid KR, Burack R, Mizuno M, Paul Morgan B

Clinical immunology : the official journal of the Clinical Immunology Society.. 2017 August 181 :24-28. Epub 05/31/2017.

Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia.

Murphy EJ, Neuberg DS, Rassenti LZ, Hayes G, Redd R, Emson C, Li K, Brown JR, Wierda WG, Turner S, Greaves AW, Zent CS, Byrd JC, McConnel C, Barrientos J, Kay N, Hellerstein MK, Chiorazzi N, Kipps TJ, Rai KR

Leukemia.. 2017 June 31 (6):1348-1354. Epub 01/24/2017.

Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.

Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, Howlett C, Skarbnik AP, Cheson BD, Zent CS, Pu JJ, Kiselev P, Foon K, Lenhart J, Henick Bachow S, Winter AM, Cruz AL, Claxton DF, Goy A, Daniel C, Isaac K, Kennard KH, Timlin C, Fanning M, Gashonia L, Yacur M, Svoboda J, Schuster SJ, Nabhan C

Annals of oncology : official journal of the European Society for Medical Oncology. 2017 May 128 (5):1050-1056. Epub 1900 01 01.

Maxed out macs: physiologic cell clearance as a function of macrophage phagocytic capacity.

Zent CS, Elliott MR

The FEBS journal.. 2017 April 284 (7):1021-1039. Epub 11/29/2016.

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.

Grever MR, Abdel-Wahab O, Andritsos LA, Banerji V, Barrientos J, Blachly JS, Call TG, Catovsky D, Dearden C, Demeter J, Else M, Forconi F, Gozzetti A, Ho AD, Johnston JB, Jones J, Juliusson G, Kraut E, Kreitman RJ, Larratt L, Lauria F, Lozanski G, Montserrat E, Parikh SA, Park JH, Polliack A, Quest GR, Rai KR, Ravandi F, Robak T, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam C, Tiacci E, Troussard X, Zent CS, Zenz T, Zinzani PL, Falini B

Blood.. 2017 February 2129 (5):553-560. Epub 11/30/2016.

Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in Chronic Lymphocytic Leukemia: Results from a Multi-Center Study of 683 Patients.

Annals of oncology : official journal of the European Society for Medical Oncology. 2017 January 27 Epub 01/27/2017.

Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.

Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, Skarbnik AP, Howlett C, Pu JJ, Sehgal AR, Strelec LE, Vandegrift A, Fitzpatrick DM, Zent CS, Feldman T, Goy A, Claxton DF, Bachow SH, Kaur G, Svoboda J, Nasta SD, Porter D, Landsburg DJ, Schuster SJ, Cheson BD, Kiselev P, Evens AM

Blood.. 2016 November 3128 (18):2199-2205. Epub 09/06/2016.

CLL: an acquired immunodeficiency disease.

Zent CS

Blood.. 2016 October 13128 (15):1908-1909. Epub 1900 01 01.

Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.

Cook EM, Lindorfer MA, van der Horst H, Oostindie S, Beurskens FJ, Schuurman J, Zent CS, Burack R, Parren PW, Taylor RP

The Journal of immunology : official journal of the American Association of Immunologists.. 2016 September 1197 (5):1762-75. Epub 07/29/2016.

What is known and unknown about chemotherapy-related cognitive impairment in patients with haematological malignancies and areas of needed research.

Williams AM, Zent CS, Janelsins MC

British journal of haematology.. 2016 September 174 (6):835-46. Epub 07/08/2016.

Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with everolimus (RAD001) and alemtuzumab: a Phase I/II study.

Zent CS, Bowen DA, Conte MJ, LaPlant BR, Call TG

Leukemia & lymphoma.. 2016 July 57 (7):1585-91. Epub 12/24/2015.

Chronic lymphocytic leukemia and proteomics: protein profiles and links with disease progression still need validation.

Zent CS

Leukemia & lymphoma.. 2016 May 57 (5):985-6. Epub 01/04/2016.

A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908).

Zent CS, Wang XV, Ketterling RP, Hanson CA, Libby EN, Barrientos JC, Call TG, Chang JE, Liu JJ, Calvo AR, Lazarus HM, Rowe JM, Luger SM, Litzow MR, Tallman MS

American journal of hematology.. 2016 March 91 (3):308-12. Epub 02/09/2016.

Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells.

Lindorfer MA, Cook EM, Tupitza JC, Zent CS, Burack R, de Jong RN, Beurskens FJ, Schuurman J, Parren PW, Taylor RP

Molecular immunology.. 2016 February 70 :13-23. Epub 12/12/2015.

Anti-CD20 monoclonal antibody-dependent phagocytosis of chronic lymphocytic leukaemia cells by autologous macrophages.

Church AK, VanDerMeid KR, Baig NA, Baran AM, Witzig TE, Nowakowski GS, Zent CS

Clinical and experimental immunology.. 2016 January 183 (1):90-101. Epub 10/28/2015.

Infectious lymphadenitis in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: a rare, but important, complication.

Bowen DA, Rabe KG, Schwager SM, Slager SL, Call TG, Viswanatha DS, Zent CS

Leukemia & lymphoma.. 2015 February 56 (2):311-4. Epub 06/25/2014.

Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates.

Zent CS, Call TG, Bowen DA, Conte MJ, LaPlant BR, Witzig TE, Ansell SM, Weiner GJ

Leukemia & lymphoma.. 2015 56 (8):2373-8. Epub 03/17/2015.

Management of chronic lymphocytic leukemia.

Stilgenbauer S, Furman RR, Zent CS

American Society of Clinical Oncology educational book. 2015 :164-75. Epub 1900 01 01.

Mutations in chronic lymphocytic leukemia and how they affect therapy choice: focus on NOTCH1, SF3B1, and TP53.

Zent CS, Burack WR

Hematology. 2014 December 52014 (1):119-24. Epub 11/18/2014.

Infection in chronic lymphocytic leukemia: parsimony has its limits.

Barr PM, Zent CS

Leukemia & lymphoma.. 2014 December 55 (12):2683-4. Epub 05/16/2014.

Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Conte MJ, Bowen DA, Wiseman GA, Rabe KG, Slager SL, Schwager SM, Call TG, Viswanatha DS, Zent CS

Leukemia & lymphoma.. 2014 September 55 (9):2079-84. Epub 02/17/2014.

Incidence of chronic lymphocytic leukemia and high-count monoclonal B-cell lymphocytosis using the 2008 guidelines.

Call TG, Norman AD, Hanson CA, Achenbach SJ, Kay NE, Zent CS, Ding W, Cerhan JR, Rabe KG, Vachon CM, Hallberg EJ, Shanafelt TD, Slager SL

Cancer.. 2014 July 1120 (13):2000-5. Epub 04/07/2014.

Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells.

Zent CS, Taylor RP, Lindorfer MA, Beum PV, LaPlant B, Wu W, Call TG, Bowen DA, Conte MJ, Frederick LA, Link BK, Blackwell SE, Veeramani S, Baig NA, Viswanatha DS, Weiner GJ, Witzig TE

American journal of hematology.. 2014 July 89 (7):757-65. Epub 04/26/2014.

Genetic risk of chronic lymphocytic leukemia: a tale of two cities.

Slager SL, Zent CS

Leukemia & lymphoma.. 2014 April 55 (4):735-6. Epub 11/01/2013.

Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia.

Baig NA, Taylor RP, Lindorfer MA, Church AK, LaPlant BR, Pettinger AM, Shanafelt TD, Nowakowski GS, Zent CS

The Journal of immunology : official journal of the American Association of Immunologists.. 2014 February 15192 (4):1620-9. Epub 01/15/2014.

The ABC of CLL: Etiology of cytopenias is important in staging and management

Barr, PM; Zent, CS.

Leuk Lymphoma. 2014; 55: 12-19.

Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL).

Shanafelt T, Lanasa MC, Call TG, Beaven AW, Leis JF, LaPlant B, Bowen D, Conte M, Jelinek DF, Hanson CA, Kay NE, Zent CS

Cancer.. 2013 November 1119 (21):3788-96. Epub 08/06/2013.

CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis.

Charbonneau B, Wang AH, Maurer MJ, Asmann YW, Zent CS, Link BK, Ansell SM, Weiner GJ, Ozsan N, Feldman AL, Witzig TE, Cunningham JM, Dogan A, Habermann TM, Slager SL, Novak AJ, Cerhan JR

Cancer immunology, immunotherapy : CII.. 2013 September 62 (9):1475-84. Epub 06/28/2013.

Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients.

Parikh SA, Rabe KG, Call TG, Zent CS, Habermann TM, Ding W, Leis JF, Schwager SM, Hanson CA, Macon WR, Kay NE, Slager SL, Shanafelt TD

British journal of haematology.. 2013 September 162 (6):774-82. Epub 07/11/2013.

A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma.

Witzig TE, Wiseman GA, Maurer MJ, Habermann TM, Micallef IN, Nowakowski GS, Ansell SM, Colgan JP, Inwards DJ, Porrata LF, Link BK, Zent CS, Johnston PB, Shanafelt TD, Allmer C, Asmann YW, Gupta M, Ballas ZK, Smith BJ, Weiner GJ

American journal of hematology.. 2013 July 88 (7):589-93. Epub 06/12/2013.

Visual loss in early-stage chronic lymphocytic leukemia.

Gonsalves WI, Zent CS, Pulido JS, Patnaik MM

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2013 June 1031 (17):e280-2. Epub 05/06/2013.

Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL).

Shanafelt TD, Ramsay AG, Zent CS, Leis JF, Tun HW, Call TG, LaPlant B, Bowen D, Pettinger A, Jelinek DF, Hanson CA, Kay NE

Blood.. 2013 May 16121 (20):4137-41. Epub 03/14/2013.

Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Kourelis TV, Gertz M, Zent C, Lacy M, Kyle R, Kapoor P, Zeldenrust S, Buadi F, Witzig T, Hayman S, Lust J, Russell S, Lin Y, Rajkumar VS, Kumar S, Leung N, Dingli D, Dispenzieri A

American journal of hematology.. 2013 May 88 (5):375-8. Epub 03/19/2013.

Phase 2 trial of daily, oral polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphpocytic leukemia

Shanafelt, TD; Call, TG; Zent, CS; Leis, JF; LaPlant, B; Bowen, DA; Roos, M; Laumann, K; Ghosh, AK; Lesnick, C; Lee, MJ; Yang, CS; Jelinek, DF; Erlichman, C; Kay, NE.

Cancer. 2013; 119(2): 363-70.

Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphpocytic leukemia with alemtuzumab and rituximab

Zent, CS; Wu, W; Bowen, DA; Hanson, CA; Pettinger, AM; Shanafelt, TD; Kay, NE; Leis, JF; Call, TG.

Leuk Lymphoma. 2013; 54(3): 476-82.

Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosis

Greipp, PT; Smoley, SA; Viswanatha, DS; Frederick, LS; Rabe, KG; Sharma, RG; Slager, SL; Van Dyke, DL; Shanafelt, TD; Tschumper, RC; Zent, CS.

Br J Haematol. 2013; 163(3): 326-33.

Survival of patients with clinically identified monoclonal B-cell lymphocytosis (MBL) relative to the age- and sex-matched general population.

Shanafelt TD, Kay NE, Rabe KG, Call TG, Zent CS, Schwager SM, Leis JF, Jelinek DF, Slager SL, Hanson CA

Leukemia.. 2012 February 26 (2):373-6. Epub 08/12/2011.

Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?

Lindorfer MA; Wiestner A; Zent CS; Taylor RP.

Oncoimmunology. 2012; 1(6): 959-61.

Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia

Zent CS; Smith BJ; Ballas ZK; Wooldridge JE; Link BK; Call TG; Shanafelt; TD; Bowen DA; Kay NE; Witzig TE; Weinier GJ.

Leuk Lymphoma. 2012; 53(2): 211-7.

Association of an increased frequency of CD14+ HLA-DR lo/neg monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL)

Gustafson MP; Abraham RS; Lin Y; Wu W; Gastineau DA; Zent CS; Dietz AB.

Br J Haematol. 2012; 156(5): 674-6.

Hematologist/oncologist disease-specific expertise and survival: lessions from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)

Shanafelt TD; Kay NE; Rabe KG; Inwards DJ; Zent CS; Leis JF; Schwager SM; Thompson CA; Bowen DA; Witzig TE; Slager SL; Call TG.

Cancer. 2012; 118(7): 1827-37.

Improving quality of life in chronic lymphocytic leukemia

Zent CS.

Leuk Lymphoma. 2012; 53(7): 1247-8.

Anti-CD20 antibody therapy for B-cell lymphomas

Taylor RP; Lindorfer MA; Zent CS.

N Engl J Med. 2012; 367(9): 876-7.

Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma

Charbonneau B; Maurer MJ; Fredericksen ZS; Zent CS; Link BK; Novak AJ; Ansell SM; WeinerGJ; Wang AH; Witzig TE; Dogan A; Slager SL; Habermann TM; Cerhan JR.

Am J Hematol. 2012; 87(9): 880-5.

Survival of patients with clinically identified monoclonal B-cell lymphocytosis (MBL) relative to the age- and sex-matched general population

Shanafelt TD; Kay NE; Rabe KG; Call TG; Zent CS; Schwager SM; Leis JF; Jelinek DF; Slager SL; Hanson CA.

Leukemia. 2012; 26(2): 373-6.

Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement

Baig NA; Taylor RP; Lindorfer MA; Church AK; LaPlant Br; Pavey ES; Nowakowski GS; Zent CS.

Leuk Lymphoma. 2012; 53(11): 2218-27.

Differentiation of chronic lymphocytic leukemia B-cells into immunoglobulin secreting cells decreases LEF-1 expression

Gutierrez A; Arendt BK; Tschumper RC; Kay NE; Zent CS; Jelinek DF.

PLoS One. 2011; 6(10): e26056.

Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia

Shanafelt TD; Drake MT; Maurer MJ; Allmer C; Rabe KG; Slager SL; Weiner GH; Call TG; Link BK; Zent CS; Kay NE; Hanson CA; Witzig TE; Cerhan JR.

Blood. 2011; 117(5): 1492-8.

FISHing for answers in proliferation centers of chronic lymphocytic leukemia lymph nodes

Zent CS; Polliack A; Tadmor T.

Leuk Lymphoma. 2011; 52(6): 946-7.

A case of hairy cell leukemia with CCND1-IGH translocation: indolent non-nodal mantle cell lymphoma revisited

Chen D; Kettering RP; Hanson CA; Colgan JP; Zent CS; Viswanatha DS.

Am J Surg Pathol. 2011; 35(7): 1080-4.

Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach

Zent CS; Kay NE.

Leuk Lymphoma. 2011; 52(8): 1425-34.

Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia

Maurer MJ; Cerhan JR; Katzmann JA; Link BK; Allmer C; Zent CS; Call TG; Rabe KG; Hanson CA; Kay NE; Slager SL; Witzig TE; Shanafelt TD.

Blood. 2011; 118(10): 2821-6.

Multi-parameter prognostication in chronic lymphocytic leukemia

Zent CS.

Leuk Lymphoma. 2011; 52(10): 1823-4.

Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin alpha-4-beta-1 (VLA-4) with natalizumab can overcome this resistance

Mraz M; Zent CS; Church AK; Jelinek DF; Wu X.

Br J Haematol. 2011; 155(1): 53-64.

Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia.

Shanafelt TD, Rabe KG, Kay NE, Zent CS, Jelinek DF, Reinalda MS, Schwager SM, Bowen DA, Slager SL, Hanson CA, Call TG

Cancer.. 2010 October 15116 (20):4777-87. Epub 1900 01 01.

CD5-positive chronic B-cell lymphoproliferative disorders: diagnosis and prognosis of a heterogeneous disease entity

Dronca RS; Jevremovic D; Hanson CA; Rabe KG; Shanafelt TD; Morice WG; Call TG; Kay NE; Collins CS; Schwager SM; Slager SL; Zent CS.

Cytometry B Clin Cytom. 2010; 58(Suppl 1): S35-41.

A comprehensive evaluation of the prognostic significance of 13q deletions in patients with B-chronic lymphocytic leukaemia

Van Dyke DL; Shanafelt TD; Call TG; Zent CS; Smoley SA; Rabe KG; Schwager SM; Sonbert JC; Slager SL; Kay NE.

Br J Haematol. 2010; 148(4): 544-50.

Detection of recurrent chromosomal defects in chronic lymphocytic leukemia/small lymphocytic lymphoma: innovations and applications

Zent CS; Van Dyke DL.

Leuk Lymphoma. 2010; 51(2): 186-7.

Autoimmune complications in chronic lymphocytic leukaemia (CLL)

Zent CS; Kay NE.

Best Pract Res Clin Haematol. 2010; 23(1): 47-59.

Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone

Bowen DA; Call TG; Shanafelt TD; Kay NE; Schwager RM; Reinalda MS; Rabe KG; Slager SL; Zent CS.

Leuk Lymphoma. 2010; 51(4): 620-7.

The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation

Zent CS; LaPlant BR; Johnston PB; Call TG; Habermann TM; Micallef IN; Witzig TE.

Cancer. 2010; 116(9): 2201-7.

Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia

Kay NE; Wu W; Kabat B; LaPlant B; Lin TS; Byrd JC; Jelinek DF; Grever MR; Zent CS; Call TG; Shanafelt TD.

Cancer. 2010; 116(9): 2180-7.

Time to test CLL p53 function

Zent CS.

Blood. 2010; 115(21): 4154-5.

Recurrent fevers, cough, and pulmonary opacities in a middle-aged man

Bauer PR; Zent CS; Aubry MC; Ryu JH.

Chest. 2010; 137(6): 1465-9.

Statin and non-steroidal anti-inflammatory drug use in relation to clinical outcome among patients with Rai stage 0 chornic lymphocytic leukemia

Shanafelt, TD; Rabe, KG; Kay, NE; Zent, CS; Call, TG; Slager, SL; Bowen, DA; Schwager, SM; Nowakowski, GS.

Leuk Lymphoma. 2010; 51(7): 1233-40.

Chronic Lymphocytic Leukemia in the Elderly: Who Should be Treated?

Zent CS.

Am Soc Clin Oncol Ed. 2010; : 268-71.

CD5+ B-cell lymphoproliferative disorders: Beyond chronic lymphocytic leukemia and mantle cell lymphoma

Jevremovic D; Dronca RS; Morice WG; McPhail ED; Kurtin PG; Zent CS.

Leuk Res. 2010; 34(9): 1235-8.

Cell-mediated immunity in chronic lymphocytic leukemia

Zent CS.

Leuk Lymphoma. 2010; 51(10): 1775-6.

Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia

Shanafelt TD; Rabe KG; Kay NE; Zent CS; Jelinek DF; Reinalda MS; Schwager SM; Bowen DA; Slager SL; Hanson CA; Call TG.

Cancer. 2010; 116(20): 4777-87.

Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia

Shanafelt T; Zent C; Byrd J; Erlichman C; LaPlant B; Ghosh A; Call T; Villalona-Calero M; Jelinek D; Bowen D; Laumann K; Wu W; Hanson C; Kay N.

Leuk Lymphoma. 2010; 51(12): 2222-9.

Chronic myeloid leukemia with p190BCR-ABL: prevalence, morphology, tyrosine kinase inhibitor response, and kinase domain mutation analysis.

Pardanani A, Tefferi A, Litzow MR, Zent C, Hogan WJ, McClure RF, Viswanatha D

Blood.. 2009 October 15114 (16):3502-3. Epub 1900 01 01.

Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab.

Awan FT, Kay NE, Davis ME, Wu W, Geyer SM, Leung N, Jelinek DF, Tschumper RC, Secreto CR, Lin TS, Grever MR, Shanafelt TD, Zent CS, Call TG, Heerema NA, Lozanski G, Byrd JC, Lucas DM

Blood.. 2009 January 15113 (3):535-7. Epub 11/13/2008.

Validation of a new prognostic index for patients with chronic lymphocytic leukemia

Shanafelt TD; Jenkins G; Call TG; Zent CS; Slager S; Bowen DA; Schwager S; Hanson CA; Jelinek DF; Kay NE.

Cancer. 2009; 115(2): 363-72.

The physician-patient relationship and quality of life: lessons from chronic lymphocytic leukemia

Shanafelt TD; Bowen DA; Venkat C; Slager SL; Zent CS; Kay NE; Reinalda M; Tun H; Sloan JA; Call TG.

Leuk Res. 2009; 33(2): 263-70.

Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemia

Nowakowski GS; Hoyer JD; Shanafelt TD; Zent CS; Call TG; Bone ND; Laplant B; Dewald GW; Tschumper RC; Jelinek DF; Witzig TE; Kay NE.

J Clin Oncol. 2009; 27(11): 1844-9.

B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome

Shanafelt TD; Kay NE; Jenkins G; Call TG; Zent CS; Jelinek DF; Morice WG; Boysen J; Zakko L; Schwager S; Slager SL; Hanson CA.

Blood. 2009; 113(18): 4188-96.

Management of autoimmune cytopenia complicating chronic lymphocytic leukemia

Zent CS; Shanafelt T.

Leuk Lymphoma. 2009; 50(6): 863-4.

Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis

Zent CS; Ding W; Reinalda MS; Schwager SM; Hoyer JD; Bowen DA; Jelinek DF; Tschumper RC; Call TG; Shanafelt TD; Kay NE; Slager SL.

Leuk Lymphoma. 2009; 50(8): 1261-8.

Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia

Shanafelt TD; Call TG; Zent CS; LaPlant B; Bowen DA; Roos M; Secreto CR; Ghosh AK; Kabat BF; Lee MJ; Yang CS; Jelinek DF; Erlichman C; Kay NE.

J Clin Oncol. 2009; 27(23): 3808-14.

Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia

Shanafelt TD; Kay NE; Rabe KG; Call TG; Zent CS; Maddocks K; Jenkins G; Jelinek DF; Morice WG; Boysen J; Schwager S; Bowen D; Slager SL; Hanson CA.

J Clin Oncol. 2009; 27(24): 3959-63.

Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia

Shanafelt TD; Byrd JC; LaPlant B; Zent CS; Call T; Secreto C; Grever MR; Lin TS; Kay NE.

Br J Haematol. 2009; 146(6): 660-4.

Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression

Ding W; Nowakowski GS; Knox TR; Boysen JC; Maas ML; Schwager SM; Wu W; Wellik LE; Dietz AB; Ghosh AK; Secreto CR; Medina KL; Shanafelt TD; Zent CS; Call TG; Kay NE.

Br J Haematol. 2009; 147(4): 471-83.

mTOR inhibitor monotherapy is insufficient to suppress viremia and disease progression in Epstein-Barr virus-driven lymphoproliferative disorders (EBV-LPD).

Holtan SG, Porrata LF, Colgan JP, Zent CS, Habermann TM, Markovic SN

American journal of hematology.. 2008 August 83 (8):688-9. Epub 1900 01 01.

Stem cell transplant for chronic lymphocytic leukemia/small lymphocytic lymphoma.

Hogan WJ, Zent CS

Leukemia & lymphoma.. 2008 May 49 (5):835-6. Epub 1900 01 01.

The role of alemtuzumab in the treatment of chronic lymphocytic leukemia.

Zent CS

Leukemia & lymphoma.. 2008 February 49 (2):175-6. Epub 1900 01 01.

Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia

Thurmes P; Call T; Slager S; Zent C; Jenkins, G; Schwager S; Bowen, D; Kay NE; Shanafelt T.

Leuk Lymphoma. 2008; 49(1): 49-56.

Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia

Palmer S; Hanson CA; Zent CS; Porrata LF; Laplant B; Geyer SM; Markovic SN; Call TG; Bowen DA; Jelinek DF; Kay NE; Shanafelt TD.

Br J Haematol. 2008; 141(5): 607-14.

Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients

Tschumper RC; Geyer SM; Campbell ME; Kay NE; Shanafelt TD; Zent CS; Nowakowski GS; Call TG; Dewald GW; Jelinek DF.

J Clin Invest. 2008; 118(1): 306-15.

CD49d expression is an independent predictor of overall survival i npatients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential

Shanafelt TD; Geyer SM; Bone ND; Tschumper RC; Witzig TE; Nowakowski GS; Zent CS; Call TG; Laplant B; Dewald GW; Jelinek DF; Kay NE.

Br J Haematol. 2008; 140(5): 537-46.

Stem cell transplant for chronic lymphocytic leukemia/small lymphocytic lymphoma

Hogan WJ; Zent CS.

Leuk Lymphoma. 2008; 49(5): 835-6.

The prognostic significant of cytopenia in chronoc lymphocytic leukaemia/small lymphocytic lymphoma

Zent CS; Ding W; Schwager SM; Reinalda MS; Hoyer JD; Jelinek DF; Tschumper RC; Bowen DA; Call TG; Shanafelt TD; Kay NE; Slager SL.

Br J Haematol. 2008; 141(5): 615-21.

MBL or CLL: which classification best categorizes the clinical course of patients with an absolute lymphocyte count , greater than or equal to 5 x 10e9/L but a B-cell lymphocyte count less than or equal to 5 x 10e9/L?

Shanafelt TD; Kay NE; Cell TG; Zent CS; Jelinek DF; LaPlant B; Morice WG; Hanson CA.

Leuk Res. 2008; 32(9): 1458-61.

Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab

Zent CS; Call TG' Shanafelt TD; Tschumper RC; Jelinek DF; Bowen DA; Secreto CR; Laplant BR; Kabat BF; Kay NE.

Cancer. 2008; 113(8): 2110-8.

Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab

Zent CS; Secreto CR; LaPlant BR; Bone ND; Call TG; Shanafelt TD; Jelinek DF; Tschumper RC; Kay NE.

Leuk Res. 2008; 32(12): 1849-56.

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

Kay NE; Geyer SM; Call TG; Shanafelt TD; Zent CS; Jelinek DF; Tschumper R; Bone ND; Dewald GW; Lin TS; Heerema NA; Smith L; Grever MR; Byrd JC.

Blood. 2007; 109(2): 405-11.

Mantle cell lymphoma presenting as a slowly enlarging lesion of the floor of mouth in a healthy 72 year old: report of a case

Rockacy J; Viozzi CF; Zent CS.

J Oral Maxillofac Surg. 2007; 65(2): 333-7.

Diagnosis and management of autoimmune complications of chronic lymphocytic leukemia/small lymphocytic lymphoma

Ding W; Zent CS.

Clin Adv Hematol Oncol. 2007; 5(4): 257-61.

Using smudge cells on routine blood smears to predict clinical outcome in chronic lymphocytic leukemia: a universally available prognostic test

Nowakowski GS; Hoyer JD; Shanafelt, TD; Geyer, SM; LaPlant BR; Call TG; Jelinek DF; Zent CS; Kay NE.

Mayo Clin Proc. 2007; 82(4): 449-53.

Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia

Shanafelt TD; Lin T; Geyer SM; Zent CS; Leung N; Kabat B; Bowen D; Grever MR; Byrd JC; Kay NE.

Cancer. 2007; 109(11): 2291-8.

Chronic lymphocytic leukemia: biology and current treatment

Zent CS; Kay NE.

Curr Oncol Rep. 2007; 9(5): 345-52.

Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients

Shanafelt TD; Bowen D; Venkat C; Slager SL; Zent CS; Kay NE; Reinalda M; Sloan JA; Call TG.

Br J Haematol. 2007; 139(2): 255-64.

Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia

Maddocks-Christianson K; Slager SL; Zent CS; Reinalda M; Call TG; Habermann TM; Bowen DA; Hoyer JD; Schwager S; Jelinek DF; Kay NE; Shanafelt TD.

Br J Haematol. 2007; 139(3): 398-404.

Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features

Bowen DA; Call TG; Jenkins GD; Zent CS; Schwager SM; Van Dyke DL; Jelinek DF; Kay NE; Shanafelt TD.

Leuk Lymphoma. 2007; 48(12): 2412-7.

Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia

Browning RL; Geyer SM; Johnson AJ; Jelinek DF; Tschumper RC; Call TG; Shanafelt TD; Zent CS; Bone ND; Dewald GW; Lin TS; Heerema NA; Gever MR; Kay NE; Byrd JC; Lucas DM.

Leuk Res. 2007; 49(1): 49-56.

Metaphase cells with normal G-bands have cryptic interstitial deletions in 13q14 detectable by fluorescence in situ hybridization in B-cell chronic lymphocytic leukemia

Stockero KJ; Fink SR; Smoley SA; Paternoster SF; Shanafelt TD; Call TG; Zent CS; Van Dyke DL; Kay NE; Dewald GW.

Cancer Genet Cytogenet. 2006; 166(2): 152-6.

Loss of TP53 due to rearrangements involving chromosome region 17p10 approximately p12 in chronic lymphocytic leukemia

Fink SR; Smoley SA; Stockero KJ; Paternoster SF; Thorland EC; Van Dyke DL; Shanafelt TD; Zent CS; Call TG; Kay NE; Dewald GW.

Cancer Genet Cytogenet. 2006; 167(2): 177-81.

Factor XII deficiency acquired by orthotopic liver transplantation: case report and review of the literature

Osborn NK; Ustundag Y; Zent CS; Wiesner RH; Rosen CB; Narayanan Menon KV.

Am J Transplant. 2006; 6(7): 1743-5.

Indolent systemic mastocytosis as the cause of a long history of unexplained hypotensive episodes

Nora EH; Hamacher KL; Zent CS; Ghosh AK.

South Med J. 2006; 99(8): 876-9.

Autoimmunity and chronic lymphocytic leukemia

Zent CS.

Leuk Lymphoma. 2006; 47(8): 1443-4.

Intravascular B-cell lymphoma (angiotropic lymphoma) with choroidal involvement

Lee HB; Pulido JS; Buettner H; Salomao D; Zent CS; Link TP.

Arch Ophthalmol. 2006; 124(9): 1357-9.

Update on risk-stratified management for chronic lymphocytic leukemia

Zent CS; Call TG; Hogan WJ; Shanafelt TD; Kay NE.

Leuk Lymphoma. 2006; 47(9): 1738-46.

Narrative review: initial management for chronic lymphocytic leukemia

Shanafelt TD; Byrd JC; Call TG; Zent CS; Kay NE.

Ann Intern Med. 2006; 145(6): 435-47.

Chronic B-cell lymphoproliferative disorders: how many diseases?

Zent CS.

Leuk Lymphoma. 2006; 47(10): 2006-7.

Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia

Shanafelt TD; Witzig TE; Fink SR; Jenkins RB; Paternoster SF; Smoley SA; Stockero KJ; Nast DM; Flynn HC; Tschumper RC; Geyer S; Zent CS; Call TG; Jelinek DF; Kay NE.

J Clin Oncol. 2006; 24(28): 4634-41.

Staging chronic lymphocytic leukemia (CLL) for prognosis at diagnosis

Zent CS; Polliack A.

Leuk Lymphoma. 2006; 47(12): 2433-4.

Clinical significance of monoclonal B cells in cerebrospinal fluid

Nowakowski GS, Call TG; Morice WG; Kurtin PJ; Cook RJ; Zent CS.

Cytometry B Clin Cytom. 2005; 63(1): 23-7.

Interphase fluorescence in situ hybridization with an IGH probe is important in the evaluation of patients with a clinical diagnosis of chronic lymphocytic leukaemia

Nowakowski GS; Dewald GW; Hoyer JD; Paternoster SF; Stockero KJ; Fink SR; Smoley SA; Remstein ED; Phyliky RL; Call TG; Shanafelt TD; Kay NE; Zent CS.

Br J Haematol. 2005; 130(1): 36-42.

Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies

Shanafelt TD; Lee YK; Call TG; Nowakowski GS; Dingli D; Zent CS; Kay NE.

Leuk Res. 2005; 30(6): 707-12.

Update on monoclonal antibody therapy in chronic lymphocytic leukemia

Zent CS; Kay NE.

Clin Adv Hematol Oncol. 2004; 2(2): 107-13.

The academic hematology-oncology firm: a model for postgraduate cancer education

Kohli M; Zent C; Hutchins LF; Safar M; Dotson P; Mehta P.

J Cancer Educ. 2004; 19(1): 45-9.

Veterans with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have a markedly increased rate of second malignancy, which is the most common cause of death

Kyasa MJ; Hazlett L; Parrish RS; Schichman SA; Zent CS.

Leuk Lymphoma. 2004; 45(3): 507-13.

Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium

Zent CS; Chen JB; Kurten RC; Kaushal GP; Lacy HM; Schichman SA.

Leuk Res. 2004; 28(5): 495-507.

Advances in the understanding of biology and prognosis in chronic lymphocytic leukemia

Zent CS; Kay NE.

Curr Oncol Rep. 2004; 6(5): 348-54.

Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia/small lymphocytic lymphoma

Kyasa MJ; Parrish RS; Schichman SA; Zent CS.

Am J Hematol. 2003; 74(1): 1-8.

The distinct gene expression profiles of chronic lymphocytic leukemia and multiple myeloma suggest different anti-apoptotic mechanisms but predict only some differences in phenotype

Zent CS; Zhan FG; Schichman SA; Bumm KHW; Lin P; Chen JB; Shaughnessy JD.

Leuk Res. 2003; 27(9): 765-74.

Advanced prostate cancer activates coagulation: a controlled study of activation markers of coagulation in ambulatory patients with localized and advanced prostate cancer

Kohli M; Fink LM; Spencer JH; Zent CS.

Blood Coagul Fibrinolysis. 2002; 13(1): 1-5.

Linezolid-induced pure red blood cell aplasia

Monson T; Schichman SA; Zent CS.

Clin Infect Dis. 2002; 35(3): E29-31.

Anemia and chronic disease

Zent C.

US Medicine. 2001; 37(5 Suppl): 5-8.

Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data

Zent CS; Kyasa MJ; Evans R; Schichman SA.

Cancer. 2001; 92(5): 1325-30.

Localized herpes simplex lymphadenitis mimicking large-cell (Richter's) transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma

Joseph L; Scott MA; Schichman SA; Zent CS.

Am J Hematol. 2001; 68(4): 287-91.

Use of HFE mutation analysis for hereditary hemochromatosis: the need for physician education in the translation of basic science to clinical practice

Kohli M; Schichman SA; Fink L; Zent CS.

South Med J. 2000; 93(5): 469-71.

Vancomycin-induced thrombocytopenia.

Govindarajan R, Baxter D, Wilson C, Zent C

American journal of hematology.. 1999 October 62 (2):122-3. Epub 1900 01 01.

Relationship between megakaryoctye mass and serum thrombopoietin levels as revealed by a case of cyclic amegakaryocytic thrombocytopenic purpura

Zent CS; Ratajczak J; Ratajczak MZ; Anastasi J; Hoffman PC; Gewirtz AM.

Br J Haematol. 1999; 105(2): 452-8.

Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation

Zent CS; Wilson CS; Tricot G; Jagannath S; Siegel D; Desikan KR; Munshi N; Bracy D; Barlogie B; Butch AW.

Blood. 1998; 91(9): 3518-23.

Rearrangements of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: in vitro and in vivo studies

Zent C; Rowley JD; Nucifora G.

Leukemia. 1997; 3(11 Suppl): 273-8.

Rearrangement of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: expression nof co-existing multiple chimeric genes with similar functions as transcriptional repressors, but with opposite tumorigneic properties

Zent C; Kim N; Hiebert S; Zhang DE; Tenen DG; Rowley JD; Nucifora G.

Current Topics in Microbiology & Immunology. 1996; 211: 243-52.

The chimeric genes AML1/MDS1 and AML1/EAP inhibit AML1B activation at the CSF1R promoter, but only AML1/MDS1 has tumor-promoter properties

Zent CS; Mathieu C; Claxton DF; Zhang DE; Tenen DG; Rowley JD; Nucifora G.

Proc Natl Acad Sci. 1996; 93(3): 1044-8.

Toxicity of anti-tuberculous medication

Zent CS.

S. Afr J of Epidemiology and Infection. 1994; 9(1): 5-9.

Drug allergy

Zent C, Smith P.

S AFr Med J. 1994; 84(5): 281-286.

Prediction of amikacin dose requirements in neutropenic patients with haematological disease

Zent CS, Allin R, Folb PI.

S. Afr Med J. 1993; 82(11): 853-854.

Books

ASH-SAP American Society of Hematology Self-Assessment Program (2016)

Chapter: Chronic lymphocytic leukemia/small lymphocytic lymphoma.

Authors: Zent CS, Call TG

Publisher: American Society of Hematology 2016

Companion to Peripheral Neuropathy: Illustrated Cases and New Developments (2010)

Chapter: Chronic lymphocytic leukemia causing multiple mononeuropathies

Authors: Mauermann ML, Zent CS, Low PA

Publisher: Saunders/Elsevier, Philadelphia 2010

Textbook of Medicine (2010)

Chapter: Disorders of the Blood

Authors: Zent C and Polliack A

Publisher: Oxford 2010

Interferons: biological activities and clinical efficacy (1997)

Chapter: Treatment options for hairy cell leukemia

Authors: Zent CS and Golomb HM

Publisher: Springer, Berlin 1997

The Chemotherapy Source Book (1996)

Chapter: Acute leukmia in adults

Authors: Zent CS, Larson RA

Publisher: Williams and Wilkins, Baltimore, MD 1996

Current Therapy in Hematology-Oncology (1995)

Chapter: Hairy Cell Leukemia

Authors: Zent CS, Golomb HM

Publisher: Mosby, St. Louis, MO 1995

South African National Formulary (1995)

Chapter: Anti-infectives for systemic use

Authors: Zent CS

Publisher: MASA, Cape Town 1995

Ratings & Comments

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.

Ratings

During this visit, did this provider spend enough time with you?

5.0

During this visit, did this provider show respect for what you had to say?

4.9

During this visit did this provider give you easy to understand information about these health questions or concerns?

4.9

During this visit, did this provider listen carefully to you?

5.0

During this visit, did this provider explain things in a way that was easy to understand?

4.9

Patient Comments

Dr. Zent was excellent in answering all our questions concerning my condition. He explained all the variables and the care needed at this time. Dr. Zent is an asset to the UR Medicine.

Sep 24, 2024

Dr. Zent took the time to listen to situation, and didn't pressure me to take specific vaccines which I appreciated. [...]

Sep 23, 2024

Dr. Zent was awesome!

Sep 16, 2024

Dr Zent is great. As a follow physician, I could tell how knowledgeable he was. Superb clinician that instantly gains your trust.

Sep 03, 2024

Dr. Zent is tops.

Sep 02, 2024

Dr. Zent is wonderful!

Aug 28, 2024

5.0

I am blessed to have such a knowledgeable, caring and professional doctor!!

Jun 30, 2024

5.0

In addition to my regular CLL checkup, I asked questions about prescriptions given by Urgent Care and about protection from insect stings. Dr. Zent always provides common sense answers and advice. He and his staff care are professional, and up to date on care for my needs.

Jun 11, 2024

5.0

Dr. Zent is outstanding. I feel very fortunate that he is my specialist.

May 09, 2024

5.0

Doctor Zent is a good physician I am glad he was recommended for my Oncologist.

May 04, 2024

5.0

I drive 5 hours [...] because Dr. Zent is the best

Apr 20, 2024

5.0

Dr. Zent is always thorough in explaining my health conditions and answer our questions.

Apr 08, 2024

4.6

Even though it was a most unusual day, my provider did not rush through the appointment.

Feb 21, 2024

5.0

Definitely would recommend Dr. Zent

Jan 24, 2024

5.0

Have recommended this provider and his team. You can't get any better care

Nov 23, 2023

5.0

I consider myself fortunate to have Dr Zent providing my care.

Nov 20, 2023

5.0

Dr. Zent saved my life

Nov 09, 2023

5.0

Dr. Zent is always willing to discuss my illness and treatment options in as much detail and depth as I request, including waiting for me to catch up when I'm taking notes.

Nov 04, 2023

5.0

Dr. Zent is an excellent doctor who provides very good care to his patients.

Aug 14, 2023

5.0

Excellent care

Jul 20, 2023

5.0

He is very good at what he does.

Jul 18, 2023

5.0

Dr. Zent considers the entire constellation of a person's health issues while monitoring CLL In my case it consists of comorbidities with MS and metastatic prostate cancer. I find it especially reassuring that he looks at the whole picture. He listens carefully and I never feel rushed. He patiently provides advice and explanations.

Jun 28, 2023

5.0

Dr. Zent is the most knowledgeable kindest doctor in the whole world

Jun 25, 2023

5.0

Dr. Zent is an exceptional doctor. I am very satisfied with the care he provides.

Jun 25, 2023

5.0

Dr. Zent always asks if you have any questions regarding what he is telling you.

Apr 07, 2023

5.0

Great drs. great staff.

Feb 14, 2023

4.2

I do not recommend.

Feb 13, 2023

3.8

Explanation sometimes became very technical.

Dec 17, 2022

5.0

Provider is of high quality

Nov 12, 2022

5.0

Always an excellent experience in the office, and always (during the work week) prompt replies to my questions through the portal. But I have to say I spent a very anxious weekend after this last visit because a question I sent on the portal wasn't replied to until Monday morning, I understand... but It was rough.

Oct 28, 2022

5.0

Excellent Care

Oct 14, 2022

5.0

Everything went very smoothly as expected.

Oct 05, 2022

5.0

Great experience

Sep 27, 2022

5.0

Really liked Dr Zent. Explained everything, very easy to understand. Showed real concern for issues

Sep 25, 2022

5.0

Saved my life.

Aug 17, 2022

5.0

Dr. Zent really cares about his patients.

Jul 21, 2022

5.0

The best doctor in the whole world

Jul 21, 2022

5.0

We are VERY FORTUNATE to have Dr. Zent on staff at WILMOT!!!

Jun 17, 2022

5.0

Dr Zent is excellent as my health care provider

Jun 15, 2022

5.0

Dr. Zent is an excellent doctor.

May 06, 2022

4.6

Dr. Zent and I had both researched the same new treatment and concluded it was not right for me, also he diagnosed a skin issue that had been misdiagnosed by my Dermatologist so I will be switching to the dermatologist who works with Dr Zent's patients (Dr. Manavva). We decided based on the experience between the last two treatments that we need to move them closer together. All decisions were very collaborative, and I felt like he listened with respect to my opinions and feedback.

Mar 24, 2022

5.0

Dr. Zent is one of two doctors I've had in my life who I consider top of their field. He is concerned with my whole health [...].

Mar 01, 2022

5.0

Dr. Zent is an excellent doctor, very knowledgeable and caring.

Feb 01, 2022